The personalized Moderna and Merck vaccine that helps prevent skin cancer from returning

When a skin melanoma is completely removed, it does not always mean the end of treatment. The real challenge may begin afterwards: preventing any tumor cells that may remain in the body from reactivating the disease months or years later, and this is precisely where the vaccine developed by Moderna and Merck aims to act. It is based on messenger RNA (mRNA), a molecule that provides cells with instructions to produce certain proteins, and is designed according to the specific characteristics of each patient’s tumor.

On August 19, 2026, both companies announced that this therapy, called intismeran autogene and previously known during development as V940 or mRNA-4157, reduced the risk of recurrence and of metastases appearing in other organs when administered alongside pembrolizumab, an immunotherapy already used to treat melanoma. The results come from an international clinical trial involving more than 1,100 patients and represent one of the most significant advances so far for personalized cancer vaccines.

A vaccine personalized to each tumor

Melanoma develops in melanocytes, the cells that produce the skin’s pigment, and is one of the forms of skin cancer with the greatest ability to spread to other parts of the body. Even when the tumor can be completely removed and no detectable disease remains, microscopic cancer cells may persist in the body and later cause a recurrence.

This treatment is being investigated precisely to reduce that risk of recurrence. Intismeran autogene is not manufactured in the same way for every patient. First, a sample of the tumor is analyzed and its mutations are studied. Based on this information, up to 34 neoantigens — abnormal proteins associated with those alterations — are selected, and a synthetic messenger RNA molecule specific to that individual is designed.

Once administered, the mRNA provides instructions for the body to temporarily produce the selected neoantigens and present them to the immune system. The aim is to activate T cells capable of recognizing those signals and directing an immune response against tumor cells with the same characteristics. It is therefore not a preventive vaccine, but a therapy intended for people who have already had cancer.

Why it is combined with immunotherapy

In the trial, the vaccine is administered alongside pembrolizumab, marketed as Keytruda, an immunotherapy that blocks the PD-1 protein. Some tumors exploit this immune-control pathway to avoid being attacked; by blocking it, the drug helps the immune system recognize and fight cancer cells more effectively.

The combination therefore pursues two complementary actions: the mRNA therapy helps highlight specific characteristics of the tumor, while immunotherapy removes one of the brakes that can prevent T cells from acting effectively. Pembrolizumab is also already used after surgery in certain melanomas. The trial therefore compares the new strategy with an established treatment.

More than 1,100 patients confirm its benefits

The INTerpath-001 study included 1,137 patients with high-risk cutaneous melanoma in stages IIB, IIC, III or IV whose tumors had been completely removed. Participants were randomly assigned to receive intismeran autogene plus pembrolizumab or pembrolizumab alone.

The main objective was to determine how long patients remained free from cancer recurrence. Researchers also assessed whether the disease later appeared in organs far from the original tumor, an especially important issue in melanoma because of its ability to metastasize.

According to preliminary results reported by Moderna and Merck, the combination produced a statistically significant and clinically meaningful improvement in both outcomes. In other words, it reduced the risk of recurrence and extended the time patients remained free from distant metastases compared with pembrolizumab alone. The study will continue to analyze other outcomes, including overall survival, to determine whether this advantage ultimately also translates into patients living longer.

What the evidence shows so far

There is an important limitation when interpreting the announcement: the companies have not yet presented the full numerical data from this stage of the trial. For now, it is known that both primary endpoints were met, but not the exact percentage reduction in risk achieved by the combination or the absolute difference between the two groups.

Previous results help explain why expectations were already high. In an earlier study involving 157 patients with a median follow-up of five years, the combination reduced the risk of recurrence or death by 49% and the risk of developing metastases or dying by 59% compared with pembrolizumab alone. Those findings showed that the benefit observed initially persisted over time.

This new trial extends that evaluation to a much larger population. In addition, no new or unexpected adverse effects were observed compared with previous studies.

However, the detailed results will only be known once they are presented at an upcoming international medical congress.

It is not yet an available vaccine against skin cancer

The advance does not mean that anyone with melanoma can already receive this therapy. Intismeran autogene remains an investigational treatment, and any future authorization will depend on a full review of the data. It is also not designed to prevent melanoma in healthy people, nor does it replace measures such as protection from ultraviolet radiation or monitoring suspicious skin lesions.

The application currently being studied is much more specific: patients with certain high-risk melanomas who have undergone surgery and in whom the aim is to prevent the disease from returning. In addition, its personalized nature makes the process more complex, as it requires analyzing the tumor, identifying its relevant mutations and producing a formulation specifically for each individual.

A step towards increasingly personalized oncology

The significance of this advance goes beyond melanoma. Moderna and Merck are studying the same technology in other tumors, including lung, bladder and kidney cancers. The fact that the first large confirmatory trial has met its objectives provides important evidence that messenger RNA can also be used to develop treatments tailored to the molecular characteristics of a specific cancer.

It remains to be seen exactly how much outcomes improve, which patients benefit most, how the treatment affects long-term survival and whether it ultimately receives authorization. But the advance changes where this technology currently stands: the possibility of producing a vaccine based on the mutations found in an individual patient’s tumor is no longer limited to small experimental studies. For the first time, it has shown a significant advantage in more than a thousand patients in a trial designed to bring this strategy closer to clinical practice.